A Phase 1/2 interventional study of pemetrexed and cisplatin in Urologic Neoplasms, sponsored by Eli Lilly and Company. Completed at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-04.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Urologic Neoplasms with a site in Spain — 3 open to participants now, 6 under way, none of them phase 3. Urologic Neoplasms · Spain.
Among the 15 studies in Urologic Neoplasms with a site in Spain, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2006, is one of 3 in phase 1/2, and was the 1st registered.
155 studies on the registry are indexed under Urologic Neoplasms; 40 are open to participants now.
Browse Urologic Neoplasms studies →3 of the 15 studies in Urologic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Australia and 5 more countries
Ages 18+
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Sites in Spain
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Australia and 11 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 30 Urologic Neoplasms studies recruiting now, 24 (80%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 2
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is close to the median of 60 across 109 interventional studies indexed under Urologic Neoplasms.
Median enrollment 265 across the 14 interventional studies, 80 across the 1 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 8 studies filed under Urologic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Urologic Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05544552Tyra Biosciences, IncSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | 2026-11 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT05614739Eli Lilly and CompanyFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Urologic Neoplasms with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the anti-tumor activity, as measured by response rate to bi-weekly pemetrexed plus cisplatin, in chemo-naive patients with diagnosed metastatic or locally advanced (non-resectable) urothelial cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed · Drug: cisplatin
Phase 1: 300 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m\^2, 400 mg/m\^2, and 500 mg/m\^2) Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy
Also known as: LY231514, Alimta
Phase 1: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles Phase 2: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy
Best Overall Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (up to 620 days)
Time to Response
Defined as time from study enrollment to the first Complete Response or Partial Response (using RECIST criteria). Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.
Time frame: baseline to response (up to 620 days)
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.
Time frame: time of response to progressive disease (up to 620 days)
Duration of Stable Disease
Defined as time from study enrollment to the first progression of disease, complete response, partial response, or death from any cause. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.
Time frame: time of no response or progression (up to 620 days)
Time to Progressive Disease
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions.
Time frame: baseline to measured progressive disease (up to 620 days)
Time to Treatment Failure (TTF)
Time from study enrollment to first observation of disease progression, death from any cause, or early discontinuation of treatment (including toxicity or if patient had stable disease after 4 cycles). TTF was censored at date of last follow-up visit for patients who did not discontinue early, who were still alive, and who had not progressed.
Time frame: baseline to stopping treatment (up to 620 days)
Progression-Free Survival
Defined as the time from study enrollment until disease progression or death from any cause.
Time frame: baseline to measured progressive disease (up to 620 days)
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
Time frame: baseline to date of death from any cause (up to 620 days)
| Milestone | Pemetrexed + Cisplatin |
|---|---|
| Started | 38 |
| Completed | 2 |
| Not completed | 36 |
| Withdrew: Adverse event | 12 |
| Withdrew: Progressive disease | 7 |
| Withdrew: Physician decision | 13 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 2 |
| Withdrew: Other - not specified | 1 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.
| participants | Pemetrexed + Cisplatin |
|---|---|
| Complete Response | 2 |
| Partial Response | 13 |
| Stable Disease | 13 |
| Progressive Disease | 1 |
| Not Evaluated | 3 |
| Not Performed | 3 |
| Missing | 3 |
Defined as time from study enrollment to the first Complete Response or Partial Response (using RECIST criteria). Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.
| days | Pemetrexed + Cisplatin |
|---|---|
| Time to Response | 111.816 ± 6.480 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.
| days | Pemetrexed + Cisplatin |
|---|---|
| Duration of Response | 184.100 ± 19.595 |
Defined as time from study enrollment to the first progression of disease, complete response, partial response, or death from any cause. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.
| days | Pemetrexed + Cisplatin |
|---|---|
| Duration of Stable Disease | 80 (71 to 103) |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions.
| days | Pemetrexed + Cisplatin |
|---|---|
| Time to Progressive Disease | 260.182 ± 22.954 |
Time from study enrollment to first observation of disease progression, death from any cause, or early discontinuation of treatment (including toxicity or if patient had stable disease after 4 cycles). TTF was censored at date of last follow-up visit for patients who did not discontinue early, who were still alive, and who had not progressed.
| days | Pemetrexed + Cisplatin |
|---|---|
| Time to Treatment Failure (TTF) | 133.5 (99 to 151) |
Defined as the time from study enrollment until disease progression or death from any cause.
| days | Pemetrexed + Cisplatin |
|---|---|
| Progression-Free Survival | 203 (137 to 285) |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
| days | Pemetrexed + Cisplatin |
|---|---|
| Overall Survival | 264.190 ± 15.130 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | — | — |
| Event | Pemetrexed + Cisplatin |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 4/38 |
| Deep vein thrombosisVascular disorders | 4/38 |
| LeukopeniaBlood and lymphatic system disorders | 3/38 |
| DiarrhoeaGastrointestinal disorders | 3/38 |
| VomitingGastrointestinal disorders | 3/38 |
| PyrexiaGeneral disorders | 3/38 |
| Urinary tract infectionInfections and infestations | 3/38 |
| NauseaGastrointestinal disorders | 2/38 |
| Renal failureRenal and urinary disorders | 2/38 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/38 |
| Event | Pemetrexed + Cisplatin |
|---|---|
| AstheniaGeneral disorders | 29/38 |
| NauseaGastrointestinal disorders | 20/38 |
| VomitingGastrointestinal disorders | 20/38 |
| AnorexiaMetabolism and nutrition disorders | 19/38 |
| DiarrhoeaGastrointestinal disorders | 18/38 |
| Mucosal inflammationGeneral disorders | 14/38 |
| Abdominal painGastrointestinal disorders | 10/38 |
| ConstipationGastrointestinal disorders | 10/38 |
| AnaemiaBlood and lymphatic system disorders | 8/38 |
| Back painMusculoskeletal and connective tissue disorders | 7/38 |
| Age Continuous(years) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 67.1 ± 8.7 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin |
|---|---|
| Female | 7 |
| Male | 31 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin |
|---|---|
| Spain | 38 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed + Cisplatin |
|---|---|
| 0 - Fully Active | 21 |
| 1 - Ambulatory, Restricted Strenuous Activity | 15 |
| 2 - Ambulatory, No Work Activities | 2 |
| Location of Primary Tumor(participants) | Pemetrexed + Cisplatin |
|---|---|
| Bladder | 32 |
| Ureter | 1 |
| Urethra | 1 |
| Renal Pelvis | 4 |
| Height(centimeters) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 166 ± 7.5 |
| Weight(kilograms) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 77.4 ± 13.2 |
The record gives a start of Aug 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin